Exploring the HER2-Negative Breast Cancer Promising Pipeline Therapies 2023 | Companies- AstraZeneca, Laekna, Novartis, Roche, Olema Pharma, Haihe Biopharma, G1 Therapeutics, and Others

DelveInsight's, "HER2-Negative Breast Cancer Pipeline Insight 2023" report provides comprehensive insights about 85+ companies and 85+ pipeline drugs in the HER2-Negative Breast Cancer pipeline landscape. It covers the HER2-Negative Breast Cancer pipeline drug profiles, including HER2-Negative Breast Cancer clinical trials and nonclinical stage products. It also covers the HER2-Negative Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

To explore more information on the latest breakthroughs in the HER2-Negative Breast Cancer Pipeline treatment landscape of the report, click here @ HER2-Negative Breast Cancer Pipeline Outlook- https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

HER2-Negative Breast Cancer Overview
HER2-Negative Breast Cancer is classified as HR-positive if its cells have receptors for the hormones estrogen and/or progesterone along with no expression of the human epidermal growth factor receptor 2 (HER2). Immunohistochemistry (IHC) test and/or Fluorescent in situ hybridization (FISH) is done to find out if cancer cells have estrogen and progesterone receptors. Common therapies for the treatment of HER2-Negative Breast Cancer include endocrine therapy (ET), ovarian suppression, aromatase inhibition, and/or CDK4/6 inhibitors.

Key Takeaways from the HER2-Negative Breast Cancer Pipeline Report
• DelveInsight's HER2-Negative Breast Cancer Pipeline report depicts a robust space with 85+ active players working to develop 85+ pipeline therapies for HER2-Negative Breast Cancer.
• The leading HER2-Negative Breast Cancer Companies include AstraZeneca, Laekna, Novartis, Jiangsu HengRui Medicine, Roche, Olema Pharmaceuticals, Haihe Biopharma, G1 Therapeutics, Merck, Chia Tai Tianqing Pharmaceutical, Tyme, Radius Pharmaceuticals, H3 Biomedicine, Eli Lilly and Company, Eagle Pharmaceuticals, and others
• Promising HER2-Negative Breast Cancer Pipeline Therapies include AZD9833, Anastrozole, Sorafenib (Nexavar, BAY43-9006), Capecitabine, AZD9833, Ipatasertib, Paclitaxel, letrozole, Zoledronic acid, bevacizumab, docetaxel, and others
• Sacituzumab Govitecan (Gilead) is being evaluated in Phase III for Hormone receptor-positive, human epidermal growth factor receptor 2 negative, metastatic breast cancer. Trodelvy (sacituzumab govitecan-hziy) is a first-inclass antibody and topoisomerase inhibitor conjugate directed to the Trop-2 receptor, a protein frequently expressed in multiple types of epithelial tumors, including metastatic triple-negative breast cancer (TNBC), where high expression is associated with poor survival and relapse. Trodelvy is also being developed as an investigational treatment for metastatic urothelial cancer, hormone receptor-positive/human epidermal growth factor receptor 2- negative (HR+/HER 2-) metastatic breast cancer and metastatic non-small cell lung cancer. Additional evaluation across multiple solid tumors is also underway. Trodelvy + checkpoint inhibitor combination is also being evaluated by Gilead in a Phase Ib/II clinical trial for metastatic triple-negative breast cancer (1L).
• RG6171/ GDC-9545 (Hoffmann-La Roche) is a selective estrogen receptor degrader (SERD) that is designed to bind to the estrogen receptor to limit its function. In addition, when SERDs bind to the estrogen receptor, they may be able to change the shape of the receptor in such a way that the cell eliminates it by degradation. A Phase II clinical trial is evaluating RG6171 for the treatment of ER-positive and HER2-negative 2/3L metastatic breast cancer. Company is expecting to file this product in 2022.
• Elacestrant/RAD1901 (Radius Pharmaceuticals) is a selective estrogen receptor degrader (SERD) out-licensed to Menarini Group, which is being evaluated for potential use as a once-daily oral treatment for HR+ breast cancer. Studies completed to date indicate that the compound has the potential for use as a single agent or in combination with other therapies to treat breast cancer. In 2018, the company initiated and opened for enrollment a phase III study (EMERALD) evaluating elacestrant as second- or third-line monotherapy in postmenopausal women with advanced/metastatic estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer patients. The study achieved its enrollment target of 466 patients who have received prior treatment with one or two lines of endocrine therapy, including a cyclin-dependent kinase (CDK) 4/6 inhibitor. In October 2021, the Radius and Menarini group jointly announced positive topline results from the EMERALD trial.

For further information, refer to the detailed HER2-Negative Breast Cancer Unmet Needs, HER2-Negative Breast Cancer Market Drivers, and HER2-Negative Breast Cancer Market Barriers, click here for HER2-Negative Breast Cancer Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

HER2-Negative Breast Cancer Emerging Drugs Profile

• Capivasertib + Fulvestrant: AstraZeneca
Capivasertib (AZD5363) is a potent selective oral inhibitor of all three isoforms of the serine/threonine kinase AKT. Capivasertib in combination with fulvestrant is currently in phase III clinical studies for the treatment of patients with locally advanced (inoperable) or metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) breast cancer following recurrence or progression on or after aromatase inhibitor (AI) therapy.

• Dalpiciclib: Jiangsu HengRui Medicine
Dalpiciclib (formerly SHR 6390) is an orally administered small molecule and selective cyclin-dependent kinase (CDK)-4/6 inhibitor. Dalpiciclib in Combination with Letrozole or Anastrozole or Fulvestrant is in Phase III clinical evaluation in patients with HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer.

Request a sample and discover the recent advances in HER2-Negative Breast Cancer Ongoing Clinical Trial Analysis and Medications, click here @ HER2-Negative Breast Cancer Treatment Landscape- https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

HER2-Negative Breast Cancer Pipeline Therapeutics Assessment
There are approx. 85+ HER2-Negative Breast Cancer companies which are developing the HER2-Negative Breast Cancer therapies. The HER2-Negative Breast Cancer companies which have their HER2-Negative Breast Cancer drug candidates in the most advanced stage, i.e. Phase III include, Jiangsu HengRui Medicine.

Dive deep into rich insights for drugs for HER2-Negative Breast Cancer Pipeline, click here @ HER2-Negative Breast Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the HER2-Negative Breast Cancer Pipeline Report
• Coverage- Global
• HER2-Negative Breast Cancer Companies- include AstraZeneca, Laekna, Novartis, Jiangsu HengRui Medicine, Roche, Olema Pharmaceuticals, Haihe Biopharma, G1 Therapeutics, Merck, Chia Tai Tianqing Pharmaceutical, Tyme, Radius Pharmaceuticals, H3 Biomedicine, Eli Lilly and Company, Eagle Pharmaceuticals, and others
• HER2-Negative Breast Cancer Pipeline Therapies- AZD9833, Anastrozole, Sorafenib (Nexavar, BAY43-9006), Capecitabine, AZD9833, Ipatasertib, Paclitaxel, letrozole, Zoledronic acid, bevacizumab, docetaxel, and others
• HER2-Negative Breast Cancer Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on HER2-Negative Breast Cancer Mergers and acquisitions, HER2-Negative Breast Cancer Licensing Activities @ HER2-Negative Breast Cancer Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. HER2-Negative Breast Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. HER2-Negative Breast Cancer - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. HER2-Negative Breast Cancer Collaboration Deals
9. Late Stage Products (Phase III)
10. Capivasertib + Fulvestrant: AstraZeneca
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II/III)
13. Inavolisib: Roche
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. Afuresertib + Fulvestrant: Laekna
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. Drug name: Company name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. HER2-Negative Breast Cancer Key Companies
23. HER2-Negative Breast Cancer Key Products
24. HER2-Negative Breast Cancer- Unmet Needs
25. HER2-Negative Breast Cancer- Market Drivers and Barriers
26. HER2-Negative Breast Cancer- Future Perspectives and Conclusion
27. HER2-Negative Breast Cancer Analyst Views
28. HER2-Negative Breast Cancer Key Companies
29. Appendix

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/out-licensing-opportunity

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.